Why the study?
Does type II diabetes mellitus increase collagen-induced platelet aggregation in patients undergoing PTCA?
Does type II diabetes mellitus increase collagen-induced platelet aggregation in patients undergoing PTCA?
Type II diabetes is associated with increased collagen-induced platelet aggregation and higher restenosis rates following PTCA, highlighting a potential need for more potent antiplatelet therapy in this population.
Answers are grounded in this paper and cite their sources.
Type II DM was associated with greater platelet aggregation and restenosis after PTCA; hypothesis-generating for intensified antiplatelet strategies.
BACKGROUND: In noninsulin-dependent type II diabetic (tIIDM) patients it was reported that ADP-induced platelet aggregation response was increased with decreased level of platelet guanylate cyclase. This study was therefore designed to examine the effects of tIIDM on collagen-induced, in-vitro platelet aggregation in percutaneous transluminal coronary angioplasty (PTCA) patients. METHODS: Twenty patients with tIIDM and 30 nondiabetic patients who had successful PTCA were included in the study. Platelet-rich plasma samples from the patients before and after PTCA were treated with in-vitro collagen and platelet aggregation waves were calculated via the turbidometric method of Born. The maximum amplitude (%) and the ratio of changes after PTCA in the study participants were measured by these waves and data were compared by student's t tests and nonparametric methods. The maximum amplitude of collagen-induced platelet aggregation before and after the procedure was also compared using variant analysis. RESULTS: The change in collagen-induced maximum amplitude of platelet aggregation in both wave 1 and wave 2 was significantly more (P < 0.001- P < 0.001) in the tIIDM group. The ratio of restenosis seen in the control coronary angiography made 6 months after intervention was found to be significantly more in the tIIDM group (P < 0.05). CONCLUSIONS: Collagen-induced platelet aggregation response was greater in patients with tIIDM than in nondiabetic patients. This makes us think that tIIDM patients could need more potent antiplatelet therapy before PTCA after the blood glucose levels have been regulated.
No takes yet. Share an insight, caveat, or question.
Sağcan et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: